Drospirenone-containing hormone therapy for postmenopausal women: Perspective on current data

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 52, Issue 2, 2007, Pages 159-164

  Archer, David F ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b The Jones Institute for Reproductive Medicine   (United States)

Author keywords

Drospirenone; Endometrium; Hypertension; Postmenopause; Progestogens

Indexed keywords

ANDROGEN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; GESTAGEN; GLUCOCORTICOID RECEPTOR; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SPIRONOLACTONE;

ABDOMINAL PAIN; ACNE VULGARIS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HORMONAL THERAPY; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VAGINA BLEEDING; WATER RETENTION; WEIGHT GAIN;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; BONE AND BONES; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; MENOPAUSE;

EID: 33947224108     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Writing Group for WHI: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333 [Evidence Level A]
2. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253 [Evidence Level A]
3. Sitruk-Ware R: Pharmacological profile of progestins. Maturitas 2004;47:277-283 [Evidence Level C]
4. Rosano GM, Vitale C, Silvestri A, et al: Metabolic and vascular effect of progestins in post-menopausal women: Implications for cardioprotection. Maturitas (suppl 1) 2003;46:S17-S29 [Evidence Level C]
5. Sitruk-Ware R: New progestogens: A review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865-883 [Evidence Level C]
6. Palacios S, Foidart JM, Genazzani AR: Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006;55:297-307 [Evidence Level C]
7. Schurmann R, Holler T, Benda N: Estradiol and drospirenone for climacteric symptoms in postmenopausal women: A double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7:189-196 [Evidence Level A]
8. Archer DF, Thorneycroft IH, Foegh M, et al: Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial. Menopause 2005; 12:716-727 [Evidence Level A]
9. Warming L, Ravn P, Nielsen T, et al: Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-111 [Evidence Level A]
10. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650 [Evidence Level C]
11. Manson JE, Hsia J, Johnson KC, et al: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534 [Evidence Level A]
12. Grodstein F, Manson JE, Stampfer MJ: Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44 [Evidence Level B]
13. Karalis I, Beever DG, Beevers M, et al: Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Pressure 2005;14:38-44 [Evidence Level B]
14. Scuteri A, Bos AJG, Brank L, et al: Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001;135:229-238 [Evidence Level B]
15. PEPI Trial Writing Group: Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA 1995;3:199-208 [Evidence Level A]
16. Preston RA, Alonso A, Panzitta D, et al: Additive effect of drospirenone/17-beta estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816-822 [Evidence Level A]
17. Preston RA, White WB, Pitt B, et al: Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804 [Evidence Level A]
18. White WB, Pitt B, Preston RA, et al: Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-1984 [Evidence Level A]